Company:  FENNEC PHARMACEUTICALS IN ... (FENC)
Form Type:  10-K
Filing Date:  3/29/2017 
CIK:  0001211583 
Address:  PO BOX 13628
68 TW ALEXANDER DRIVE
 
City, State, Zip:  RESEARCH TRIANGLE PARK, North Carolina 27709 
Telephone:  (919) 636-4530 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$9.95  
Change: 
-0.19 (-1.87%)  
Trade Time: 
Nov 24  
Market Cap: 
$157.91M
Trade FENC now with 

© 2017  
Description of Business
Fennec Pharmaceuticals Inc. ("Fennec," the "Company," "we," "us," or "our") is a biopharmaceutical company focused on the development of Sodium Thiosulfate ("STS") for the prevention of platinum-induced ototoxicity in pediatric cancer patients. We incorporated under the Canada Business Corporations Act ("CBCA") in September 1996. Effective on August 25, 2011, the Company continued from the Canada Business Corporations Act to the Business Corporations Act (British Columbia) (the "Continuance"). The Continuance was approved by the shareholders of Fennec at the Company's June 2011 Annual and Special Meeting and by resolution of the Board of Directors on August 10, 2011. We have three wholly-owned subsidiaries: Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc., a Canadian company. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.
Register and access this filing in:     
  FORM 10-K
    PART I
      Item 1. Business Overview
      Item 1A. Risk Factors
      Item 1B. Unresolved Staff Comments
      Item 2. Properties
      Item 3. Legal Proceedings
      Item 4. Mine Safety Disclosures
    Part II
      Item 5. Market for the Registrant's Common Equity, Related ...
      Item 7. Management's Discussion and Analysis of Financial ...
        Results of Operations
        Liquidity and Capital Resources
      Item 7A. Quantitative and Qualitative Disclosures About ...
      Item 8. Financial Statements and Supplementary Data
      Item 9. Changes in and Disagreements with Accountants on ...
      Item 9A. Controls and Procedures
      Item 9B. Other Information
    PART III
      Item 10. Directors, Executive Officers and Corporate Governance
        NAME AND TITLE
      Item 11. Executive Compensation
        COMPENSATION TABLE
        OPTIONS
      Item 12. Security Ownership of Certain Beneficial Owners and ...
      Item 13. Certain Relationships and Related Transactions, and ...
      Item 14. Principal Accounting Fees and Services
    PART IV
      Item 15. Exhibits, Financial Statement Schedules
    SIGNATURES
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    BALANCE SHEET
    INCOME STATEMENT
    CASH FLOW
    STOCKHOLDERS EQUITY
    Notes to the Consolidated Financial Statements
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 99.1